GLAUKOS Corp
GLAUKOS Corp is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.
The next scheduled catalyst is Next quarterly earnings (projected) on December 28, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 27.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 46 concluded trials, 85% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 28, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2027 | Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | Trial Milestone | Phase 2 |
| May 15, 2027 | Travoprost Intraocular Implant + iStent Infinite | Trial Milestone | Phase 4 |
| September 15, 2027 | Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus | Trial Milestone | Phase 4 |
| March 15, 2028 | Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant | Trial Milestone | Phase 2 |
| June 15, 2028 | Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant | Trial Milestone | Phase 3 |
Track GKOS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open GKOS in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.